Integra LifeSciences Holdings Corporation (IART) – What Are Investment Firms Saying About This Stock?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been assigned an average rating of “Reduce” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.12.

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company set a $13.00 target price on shares of Integra LifeSciences and gave the stock an “equal weight” rating in a report on Thursday, October 22nd. JPMorgan Chase & Co. lowered their price target on shares of Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating on the stock in a report on Thursday, October 22nd. Zacks Research lowered shares of Integra LifeSciences from a “hold” rating to a “strong sell” rating in a research report on Monday, October 26th. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, BMO Capital Markets restated a “market perform” rating and set a $14.00 price objective (down from $15.00) on shares of Integra LifeSciences in a research report on Thursday, October 22nd.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors have recently bought and sold shares of the business. Diversified Trust Co purchased a new stake in shares of Integra LifeSciences during the third quarter worth about $243,000. Russell Investments Group Ltd. boosted its stake in Integra LifeSciences by 372.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 170,428 shares of the life sciences company’s stock worth $2,775,000 after purchasing an additional 134,320 shares during the period. Maryland State Retirement & Pension System purchased a new stake in Integra LifeSciences during the 3rd quarter valued at approximately $244,000. Illinois Municipal Retirement Fund purchased a new stake in Integra LifeSciences during the 3rd quarter valued at approximately $584,000. Finally, Fulcrum Asset Management LLP raised its position in shares of Integra LifeSciences by 15,420.0% during the third quarter. Fulcrum Asset Management LLP now owns 13,968 shares of the life sciences company’s stock valued at $232,000 after buying an additional 13,878 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded down $0.70 during midday trading on Friday, hitting $13.42. The company had a trading volume of 871,884 shares, compared to its average volume of 1,248,525. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.49. The company has a fifty day moving average of $14.55 and a two-hundred day moving average of $14.12. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 78.94, a PEG ratio of 0.53 and a beta of 1.28. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.03. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. The business had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. On average, equities research analysts expect that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.